Since the first approval of pembrolizumab in 2014 for the treatment of advanced or unresectable melanoma, seven antibodies targeting PD-1 or PD-L1 have been approved by the Food and Drug Administration (FDA) for the treatment of solid tumors or onco-hematological diseases (lymphoma) [2]. Here, CD274 is linked to melanoma.